Welcome to our dedicated page for Anteris Technologies Global SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anteris Technologies Global Corp. filings document the regulatory record of a structural heart medical device issuer developing the DurAVR® Transcatheter Heart Valve for aortic stenosis. Its reports and material-event filings cover operating and financial results, Form 10-K disclosures, clinical and regulatory activity tied to the PARADIGM trial, research and development spending, risk factors and management discussion of liquidity and operations.
The company’s SEC filings also describe material agreements, facility leases, strategic investment and public offering activity, common-stock capital structure, registration statements, equity incentive awards, director and officer governance matters, subsidiary arrangements and disclosures furnished for ASX reporting. These documents connect AVR’s device-development program with financing, governance and public-company reporting obligations.
Anteris Technologies Global Corp. entered into a Sales Agreement with TD Securities (USA) LLC (TD Cowen) to establish an at-the-market stock offering program. The company may, at its discretion, sell shares of common stock with an aggregate offering price of up to $250,000,000 through TD Cowen as agent or principal.
Sales can be made over time on Nasdaq or through negotiated block trades, with TD Cowen earning a 3.0% commission on gross proceeds from shares it sells as agent. Anteris currently plans to use any net proceeds primarily to fund development of its DurAVR® Transcatheter Heart Valve System, and the remainder for working capital and general corporate purposes.
Anteris Technologies Global Corp. filed a prospectus supplement establishing an at-the-market offering program to sell up to $250,000,000 of its common stock through TD Securities (USA) LLC (TD Cowen) as sales agent. Sales may occur from time to time on Nasdaq or other trading venues; TD Cowen will receive 3.0% of gross proceeds as compensation.
The supplement uses an example price of $9.00 per share (last reported sale on May 21, 2026) and illustrates issuance of 27,777,777 shares, resulting in up to 125,009,831 shares outstanding under that example. Net proceeds are intended primarily for continued development of the DurAVR® THV System, with remaining amounts for working capital and general corporate purposes.
Anteris Technologies Global Corp. reported that Susan Elizabeth Knight filed an initial ownership statement on Form 3 as a director. The filing does not list any stock or option transactions or current holdings, and serves to formally register her status as an insider with the SEC.
Anteris Technologies Global Corp. director Stephen Denaro filed an initial ownership report showing indirect holdings in the company. The filing lists 23,722 CHESS Depositary Interests in Anteris common stock, held through Australian custodial arrangements and trust structures where Denaro is a beneficiary or is deemed to beneficially own the interests.
Denaro is also reported to hold several indirect stock option positions over Anteris common stock. These include options over 40,000 shares at an exercise price of $9.31 expiring on June 13, 2027, 80,500 shares at $17.35 expiring on September 15, 2028, and 50,000 shares at $16.63 expiring on June 19, 2029, each vesting in three annual installments.
Anteris Technologies Global Corp. files a prospectus supplement to update its shelf prospectus and to register 9,103,796 shares of common stock for resale by the selling stockholders identified in the Prospectus. The supplement attaches the Company’s Form 10-Q and Form 8-K and states the registered shares “may be offered for sale by the selling stockholders” pursuant to the Prospectus.
For context, the number of shares outstanding was 97,342,203 as of May 11, 2026. The supplement amends and supersedes portions of the Prospectus where indicated and should be read together with the Prospectus.
Anteris Technologies Global Corp. ownership update: Nantahala Capital Management, LLC and principals report beneficial ownership of 6,143,154 shares of common stock as of March 31, 2026. The filing states this equals 6.28% of the class and includes 612,244 shares that may be acquired within sixty days through exercise of convertible securities.
The filing is an amended Schedule 13G/A identifying Nantahala as the beneficial owner and Messrs. Wilmot B. Harkey and Daniel Mack as control persons with shared voting and dispositive power over the reported shares.
Anteris Technologies Global Corp. announced that its Board appointed Susan Knight and Stephen Denaro as directors effective May 11, 2026 (May 12, 2026 in Australia). Knight becomes a Class I director with a term running to the 2028 annual meeting and will join the Audit and Risk Committee. Denaro becomes a Class II director with a term running to the 2026 annual meeting. As non-employee directors, they will receive cash retainers and equity compensation under the company’s Non-Employee Director Compensation Policy, including an initial restricted stock unit grant to Knight valued at $250,000, subject to stockholder approval, and potential annual RSU awards valued at $125,000. Denaro also receives an annual fee of AUD $57,645 for serving as company secretary to certain Australian subsidiaries. The company entered into indemnification agreements with both directors, providing protection to the fullest extent permitted under Delaware law.
Anteris Technologies Global Corp. furnished its first-quarter 2026 results, highlighting heavy investment in its pivotal DurAVR heart valve trial. For the three months ended 31 March 2026, net operating cash outflows were $28.7 million, mainly tied to clinical, regulatory and manufacturing work on the Trial.
Research and development expenses were $17.5 million, driven by expanded manufacturing, quality processes, added headcount and clinical costs as more patients were enrolled. The company also reported related-party payments of $2.3 million for director fees and executive compensation during the quarter. The Trial is a ~1,000-patient randomized study comparing the DurAVR transcatheter valve to existing TAVR devices, supported in the U.S. by Medicare and Medicaid coverage under National Coverage Determination 20.32.
Anteris Technologies Global Corp. reported a larger quarterly operating loss as it scales development of its DurAVR THV heart valve, but now holds a significantly stronger cash position after major equity financings. For the three months ended March 31, 2026, net sales were $0.5 million, down slightly from $0.6 million a year earlier, reflecting the wind-down of legacy product distribution.
Research and development expense rose to $17.5 million and selling, general and administrative costs to $6.9 million, driving a net loss of $22.9 million compared with $21.9 million in 2025. Other income increased to $1.7 million, mainly from interest on cash.
The company strengthened its balance sheet with a January 2026 underwritten public offering of 40.0 million shares and a 15.7 million-share private placement to Medtronic at $5.75 per share, generating about $320 million in gross proceeds. Cash, cash equivalents and restricted cash rose to $283.2 million from $12.6 million, and stockholders’ equity improved to $278.4 million from a small deficit, despite an accumulated deficit of $393.6 million. Management believes current cash will fund operations for at least 12 months.
Operationally, Anteris advanced its global pivotal Trial for DurAVR THV, supported by FDA IDE approval and, in April 2026, U.S. Medicare reimbursement eligibility under an existing TAVR coverage determination, enabling U.S. site activation and initial patient enrollment in May 2026. The company continues to consolidate a variable interest entity, v2vmedtech, but has elected to terminate its development agreement after quarter-end, incurring a $0.4 million break fee and removing ongoing funding obligations.
Management again disclosed that disclosure controls and procedures were not effective due to previously identified material weaknesses in internal control over financial reporting, although remediation efforts, including enhanced segregation of duties and control documentation, are under way. Anteris remains an emerging growth and smaller reporting company and expects continued losses as it invests heavily in clinical, regulatory, and manufacturing capabilities to pursue FDA Premarket Approval and CE Mark for DurAVR THV.
Anteris Technologies Global Corp. ownership disclosure: Sio Capital Management, LLC amended its Schedule 13G to report beneficial ownership of 5,382,965 shares of Common Stock as of March 31, 2026. The filing states this represents 5.54% of the class based on 97,232,054 shares outstanding as of February 25, 2026.
The statement clarifies voting and dispositive power as shared and explains relationships among Sio, Sio GP, LLC and Michael Castor; the filing includes a disclaimer about formal beneficial‑owner attribution.